ABSTRACT

The present disclosure relates to a PD-1 binding protein and the pharmaceutical use. Specifically, the present disclosure relates to an anti-PD-1 antibody, a pharmaceutical composition containing the antibody, a method for treating inflammatory or autoimmune diseases, and the pharmaceutical use.